Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 6/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | UGCG | Q16739 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5752139 | 0.92 | BACE1 (0.39) | PTGER4BACE1BACE2PSMB5HTT | |
| SCHEMBL5751536 | 0.91 | PTGER4 (0.38) | PTGER4BACE1BACE2PSMB5HTT | |
| SCHEMBL1900082 | 0.90 | PTGER4 (0.38) | PTGER4BACE1BACE2UGCG | |
| SCHEMBL5751951 | 0.88 | PTGER4 (0.40) | PTGER4BACE1BACE2UGCGACACB | |
| SCHEMBL5752436 | 0.87 | BACE1 (0.38) | PTGER4BACE1BACE2HTTMEN1 | |
| SCHEMBL5753753 | 0.85 | PTGER4 (0.36) | PTGER4BACE1BACE2UGCGCYP1A2 | |
| SCHEMBL1900536 | 0.84 | PSMB5 (0.48) | PTGER4BACE1BACE2PSMB5HTT | |
| SCHEMBL5751713 | 0.84 | BACE1 (0.34) | PTGER4BACE1BACE2HTTMEN1 | |
| SCHEMBL5753313 | 0.84 | BACE1 (0.35) | PTGER4BACE1BACE2HTTMEN1 | |
| SCHEMBL5754766 | 0.83 | BACE1 (0.34) | PTGER4BACE1BACE2HTTUGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | claimed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | claimed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | claimed |
| US-7897175-B2 | Cholesteryl ester transfer protein (CETP) such as torcetrapib; 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase); two drugs are separate from each other; improved chemical stability of the HMG-CoA reductase inhibitor | BEND RESEARCH, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-1961419-B1 | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor | PFIZER PROD INC (US) | 2010-03-24 | — | — | EP | disclosed |
| EP-1961419-A1 | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor | Pfizer Products Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1581210-B1 | DOSAGE FORMS COMPRISING A CETP INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR | PFIZER PROD INC (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1653926-A1 | DOSAGE FORMS PROVIDING CONTROLLED RELEASE OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND IMMEDIATE RELEASE OF HMG-COA REDUCTASE INHIBITORS | Pfizer Products Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| EP-1581210-A1 | DOSAGE FORMS COMPRISING A CETP INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR | Pfizer Products Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1578415-A1 | DOSAGE FORMS COMPRISING A CETP INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20040197398-A1 | Dosage forms comprising a CETP inhibitors and an HMG-CoA reductase inhibitor | PFIZER INC. | 2004-10-07 | — | — | US | disclosed |
| US-20040185102-A1 | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor | PFIZER INC | 2004-09-23 | — | — | US | disclosed |
| US-20040132771-A1 | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors | PFIZER INC | 2004-07-08 | — | — | US | disclosed |
| WO-2004056358-A1 | DOSAGE FORMS COMPRISING A CETP INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056395-A1 | COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-COA REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056359-A1 | DOSAGE FORMS COMPRISING A CETP INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056396-A1 | DOSAGE FORMS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS WITH IMPROVED PERFORMANCE | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040197398-A1 | Dosage forms comprising a CETP inhibitors and an HMG-CoA reductase inhibitor | CETP, HMGCR, MTTP | PTGER4 2003/4885BACE1 1951/4885BACE2 3216/4885 |
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | PTGER4 1632/4885BACE1 835/4885BACE2 1392/4885 |
| US-20040185102-A1 | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor | CETP, HMGCR, MTTP | PTGER4 2970/4885BACE1 1994/4885BACE2 3588/4885 |
| US-20040132771-A1 | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors | CETP, HMGCR, CHLSN | PTGER4 2907/4885BACE1 1758/4885BACE2 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.